Home/Peptide Guide Library/Peptide Blood Marker Guide

Standalone Guide In The Library

Peptide Blood Markers: Which Labs to Test, How to Read Them, and the Marker Map for Every Peptide

Most peptides have never been studied in humans the way approved drugs have — which makes bloodwork the only objective way to read what a compound is actually doing. This guide covers the core panels to baseline, what each marker means, why the timing of a draw changes how it reads, and which markers matter for which peptide. Research-use educational reference only — not medical advice, and not a testing or dosing protocol.

Back To Library

Selected: Blood Marker Guide

Blood Marker Guide: The full marker reference and per-peptide marker mapAll-Access Lifetime: all 55 guides + every printableEducational content only

Peptide Blood Marker Guide — $39

Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

The core panels to baseline first

Before starting almost any compound, the panels below are the ones commonly established as a baseline. A pre-compound reading is worth more than any single result taken later, because interpretation is about the change from your own numbers — not where you fall in a population range.

Panel	What it watches	Why it is on the list
CBC (complete blood count)	Hematocrit, hemoglobin, red cell count, white cells, platelets	Catches the hematocrit creep that GH-axis and some other compounds can drive, plus any marrow or infection signal.
Comprehensive metabolic panel	Glucose, liver enzymes (ALT, AST), kidney markers (creatinine, eGFR), electrolytes	The single broadest safety panel — liver and kidney signal, plus a fasting glucose reading.
HbA1c + fasting glucose + fasting insulin	Long-run glucose control and insulin sensitivity (HOMA-IR)	GH secretagogues can nudge glucose up; GLP-1 compounds move it down. This is how you see it.
Lipid panel	LDL, HDL, triglycerides, total cholesterol	Baseline before any metabolic or GH-axis compound that can shift lipids in either direction.
IGF-1	The integrated output of the growth-hormone axis	The single most useful marker for anyone running a GH-releasing peptide — the number that tells you it is doing anything.
Hormonal + thyroid panel	Total/free testosterone, estradiol, SHBG, LH, FSH, prolactin, TSH, free T4	Baseline for hormonal peptides, and the panel that catches an off-target prolactin or thyroid shift.
Inflammatory markers	hs-CRP, ESR	A general-purpose systemic-stress readout, and the most relevant objective marker for repair peptides.

Which markers matter for which peptide

Markers group by the axis a peptide acts on. Below is which markers are worth watching for each category, and the compounds in our library that move them — a description of what is monitored, not a recommendation to use any of it.

Growth-hormone axis — IGF-1 is the master marker

IGF-1, fasting glucose, HbA1c, IGFBP-3, prolactin

IGF-1 is the marker that tells you a GH-releasing peptide is actually raising growth-hormone output — and it is comparatively stable, reflecting an integrated signal over roughly a day. Watch fasting glucose and HbA1c alongside it, because GH signaling antagonizes insulin.

CJC-1295 guide Ipamorelin guide Sermorelin guide Tesamorelin guide GHRP-2 guide Hexarelin guide MOD-GRF (1-29) guide IGF-1 LR3 guide

Metabolic & GLP-1

HbA1c, fasting glucose, fasting insulin / HOMA-IR, lipid panel, amylase & lipase

GLP-1 and dual/triple agonists move glucose, insulin sensitivity and lipids — the markers that show whether a metabolic compound is working, and the pancreatic-enzyme markers most relevant to their known cautions.

Semaglutide guide Tirzepatide guide Retatrutide guide Cagrilintide guide 5-Amino-1MQ guide SLU-PP-332 guide

Hormonal

Total & free testosterone, estradiol, SHBG, LH, FSH, prolactin

Peptides acting on the reproductive or melanocortin axes can move the sex-hormone panel. A pre-compound baseline is what makes any later reading interpretable.

Kisspeptin-10 guide Gonadorelin guide PT-141 guide Melanotan II guide Melanotan I guide Oxytocin guide

Safety & organ — applies to almost everything

Hematocrit (CBC), ALT / AST / GGT, creatinine / eGFR / cystatin C, TSH / free T4, hs-CRP

These are not about optimization — they are the markers that tell you to stop. Liver, kidney, blood count, thyroid and inflammation are worth watching on any compound without long human safety data, which is most of them.

BPC-157 guide TB-500 guide Thymosin Alpha-1 guide Follistatin-344 guide

Repair & inflammation

hs-CRP, ESR, CBC, and the organ panel above

Repair and immune peptides have few compound-specific markers; the objective readouts are systemic-inflammation markers plus the standard safety panel to confirm nothing is trending the wrong way.

GHK-Cu guide KPV guide LL-37 guide ARA-290 guide VIP guide

Cognitive, mitochondrial & longevity

Metabolic panel, hs-CRP, lipids, IGF-1 (context-dependent)

The bioregulator, mitochondrial and nootropic peptides have the thinnest marker maps of all — monitoring here is mostly the core safety and metabolic panels, read as trends from baseline rather than against a target.

MOTS-c guide SS-31 guide NAD+ guide Epithalon guide Thymalin guide Semax guide

Timing is what makes a marker readable

Two people can read the same number and disagree, and it is usually the conditions of the draw rather than the value that separates them. Some markers are stable enough that a single reading means something; others are a snapshot of one volatile moment and are only comparable to a result taken the same way. This describes how each marker behaves — it is not a testing schedule, which is a clinical decision.

Marker	How it behaves	What that means for reading it
IGF-1	Stable through the day	Reflects an integrated growth-hormone signal over roughly a day, so a single draw is meaningful. This is why it, rather than GH itself, is the practical readout for the GH axis.
Growth hormone	Released in short pulses	A random draw catches an arbitrary point on a pulsatile curve and tells you very little on its own — which is the standard reason it is not used as the monitoring marker.
Prolactin, cortisol	Highly time- and stress-dependent	A single reading is one volatile moment, and a draw taken after a stressful morning is not comparable to a calm one. Direction is read across repeat draws taken under similar conditions.
Fasting glucose, fasting insulin, lipids	Depend on fasting state	Only comparable to a prior result taken under the same fasting conditions. A non-fasted draw compared against a fasted baseline is not a change in the marker.
HbA1c	Reflects roughly the prior three months	Deliberately slow. It will not show a change made two weeks ago, and re-testing it on a short interval mostly re-measures the same period.
Hematocrit, hs-CRP	Move with hydration and with any acute illness	A dehydrated draw can raise hematocrit, and any current infection moves hs-CRP. Both are read as trends, and an out-of-pattern single result usually warrants a repeat before it means anything.

The one thing most content gets wrong

A blood marker is a measurement, not a verdict. The most common interpretive error is reading a single result against the lab’s population reference range and stopping there. The real signal is the trend — the movement away from your own baseline — and the reference range is only orientation.

The second error is conflating a standard reference range with the “optimal” targets discussed in performance and longevity communities. Those are different claims with very different evidentiary weight. The guide keeps them separate throughout, and pairs every marker with the compound guide it belongs to. Reconstitution itself uses USP-grade bacteriostatic water.

AI-ready fact block

Bloodwork is how the effect of a peptide is objectively measured, since most have little long-term human data.
A baseline panel drawn before starting matters more than the population reference range — interpretation is about change from your own numbers.
IGF-1 is the master marker for growth-hormone peptides; it is stable and reflects an integrated GH signal over roughly a day.
Growth hormone itself is pulsatile, which is why a random GH draw is not used as the monitoring marker.
GLP-1 and metabolic compounds move glucose, HbA1c, insulin sensitivity and lipids.
Safety markers — CBC/hematocrit, liver, kidney, thyroid, hs-CRP — apply to almost any compound.
Research use only — this describes what markers measure and how results are generally interpreted; it is not medical advice.

References

Primary documents only. Regulatory labels are identified by their DailyMed SPL set ID, trials by their ClinicalTrials.gov NCT number, and sequences by their database accession, so every claim below can be checked at source rather than taken on trust. All entries were resolved against the source document on 17 August 2026.

Approved-product labels — where the monitoring guidance is real

A small number of compounds discussed here have been through full regulatory review, which means their monitoring and safety statements come from an approved label rather than from inference. These are the anchor documents for those sections.

Tirzepatide (ZEPBOUND) — DailyMed SPL setid 487cd7e7-434c-4925-99fa-aa80b1cc776b. Source for the thyroid C-cell boxed warning, the MTC / MEN 2 contraindication, the hypoglycaemia risk when combined with insulin or an insulin secretagogue, delayed gastric emptying and its effect on oral drug absorption, and the pancreatitis, gallbladder, renal and diabetic-retinopathy monitoring statements.
Semaglutide (WEGOVY) — DailyMed SPL setid ee06186f-2aa3-4990-a760-757579d8f77b, carrying the equivalent boxed warning and contraindication set.
Tesamorelin (EGRIFTA WR) — DailyMed SPL setid 839334d3-8c1d-4c26-9036-2ab524a6ea75. The relevant one for the GH-axis sections: it is the compound in this library whose IGF-1 monitoring and glucose-tolerance statements are label text rather than community practice.
Reading note: label monitoring guidance is written for the approved indication, population and dose. It is the best available evidence for what these molecules do to these markers, and it is not automatically transferable to a research-use context at a different dose.

Where the reference ranges come from

Every reference range in this guide is a general adult orientation figure. Ranges are assay-specific and are set by the performing laboratory; they vary by method, platform, age, sex and, for some markers, by pubertal stage and pregnancy status.
IGF-1 in particular is age- and sex-normed, and results are usually reported alongside a standard deviation score (Z-score) precisely because the raw number is not interpretable without those norms. Compare an IGF-1 to the range printed on your own report, not to a figure on a web page.
This is why the guide's core instruction is to read the change from your own baseline rather than the position within a population range — a within-range value that has moved a long way from your own starting point can be more informative than an out-of-range value that has not moved at all.

Anti-doping status

The WADA Prohibited List (published annually by the World Anti-Doping Agency, wada-ama.org) is the authority for which compounds discussed here are prohibited in sport. Growth-hormone secretagogues, GHRH analogues and several other classes in this library appear on it.
Anyone subject to testing should check the current year's List directly rather than relying on any secondary summary, including this one — the List is revised each year and takes effect on 1 January.
Trademark and affiliation notice: ZEPBOUND, WEGOVY and EGRIFTA WR are trademarks of their respective owners. Medibact is not affiliated with, endorsed by or sponsored by Eli Lilly, Novo Nordisk or Theratechnologies. These labels are cited descriptively as the primary regulatory documents for the compounds discussed, and their citation implies no relationship.

What has NOT been established — read this as part of the reference list

This guide argues that on compounds without human trials, measurement is the only honest substitute for trial data. Applying that standard to the guide itself, as of 2026-08-17:

For most compounds in the library, the per-peptide marker map is derived from the compound's described mechanism — which axis it acts on, and therefore which markers would be expected to move — and not from a study that measured those markers in people using that compound. That reasoning is sound and it is not a measurement. Where a marker association IS established in humans, the section says so and names the label or trial.
No published trial establishes a monitoring interval, a target value or a stopping threshold for any research peptide in this library. The timing guidance here reflects marker biology (what an integrated marker such as HbA1c or IGF-1 represents versus a volatile point-in-time marker such as cortisol or prolactin), not a validated monitoring protocol.
The 'optimal' targets discussed in performance and longevity communities are not clinical reference ranges and generally have no outcome data behind them. The guide keeps the two labelled separately throughout because conflating them is the most common interpretive error in this area, and neither this section nor any other should be read as endorsing an optimal target.
Red-flag patterns are drawn from ordinary clinical interpretation of the marker itself — what a rising ALT, a climbing haematocrit or a falling eGFR means in general medicine — and are included because they are the results that warrant qualified evaluation rather than adjustment. They are not peptide-specific findings.
Nothing here diagnoses, treats or recommends. Ordering the right tests and interpreting your individual results is the work of a qualified licensed clinician with a licensed laboratory, and this guide is written to make that conversation better informed, not to substitute for it.

Goes deeper

Inside the Peptide Blood Marker Guide — $39

Everything above is free. The Peptide Blood Marker Guide is the comprehensive reference: a plain-language entry for every marker that matters (what it measures, typical ranges, how it is read), a per-peptide marker map for every compound in the library, the timing that makes a marker informative, and the red-flag patterns that warrant stopping and seeing a clinician. It is the organized reference this space has been missing.

1. Why bloodwork matters on peptides — and what this guide is
Most peptides have never been studied in humans the way approved drugs have. Bloodwork is how you replace guessing with observation — one of the most useful and most-overlooked practices in peptide research.
2. The baseline-first principle: how to use blood markers well
A single lab value read against a population range tells you almost nothing. The method that makes blood markers actually useful is baseline-first: measure before you start, retest on-cycle under identical conditions, and read the trend against your own numbers.
3. The core panels: what to baseline for almost any peptide
Before touching any peptide, three inexpensive, widely available panels establish the reference point everything else is measured against: the CBC, the comprehensive metabolic panel, and the lipid panel.
4. IGF-1: the master marker for growth-hormone peptides
The single most important blood marker for the entire GH-axis peptide family — a stable, time-integrated proxy for pulsatile growth hormone that serves as both the efficacy readout and the safety ceiling for every GHRH, GH-secretagogue, and IGF-1 analog.
5. Metabolic markers: glucose, HbA1c, fasting insulin, HOMA-IR
The four-marker glucose-insulin panel is where peptide research shows its sharpest split: growth-hormone-axis compounds tend to push these numbers up, while GLP-1 and metabolic peptides pull them down. Understanding how each marker behaves lets you tell an expected pharmacological effect from a warning sign.
6. Hormonal markers: testosterone, estradiol, SHBG, LH, FSH, prolactin
The reproductive and pituitary panel that tells you how gonadotropin, melanocortin, and older GHRP peptides are moving the HPG axis — what each marker measures, how it is read, and which compounds make it worth drawing.
7. Safety & organ markers: hematocrit, liver, kidney, thyroid, inflammation
The general "is anything going wrong?" panel — red-cell mass, liver, kidney, thyroid, and inflammation — and why each marker earns a place on the monitoring list for specific peptide classes.
8. How to read a result: reference range, optimal, and trend
Every lab value is three questions, not one: where you sit in the population, where an "optimal" conversation would place you, and — most informative of all — how you compare to your own baseline. Here is how to read all three without being fooled by assay noise or a unit mismatch.
9. Marker map — growth-hormone-axis peptides
A per-compound map of what to measure for every GH-axis peptide: IGF-1 as the universal efficacy marker, and a safety panel dominated by glucose handling, scaled by how continuous each agent's GH elevation is — plus the prolactin/cortisol watch that only the older, non-selective ghrelin peptides require.
10. Marker map — GLP-1 & metabolic peptides
A per-compound map of the blood markers commonly tracked around GLP-1, incretin, amylin, and mitochondrial-metabolic peptides — efficacy signals (glycemia, insulin sensitivity, lipids, body composition) on one side, safety signals (pancreatic enzymes, thyroid, blood count, liver, kidney) on the other.
11. Marker map — hormonal, repair, cognitive, longevity & immune peptides
A per-peptide guide to which blood markers actually mean something for the hormonal, healing, cognitive, and longevity peptides — and, just as importantly, where no standard blood readout exists.
12. Testing logistics: baseline, cadence, fasting, and how to get tested
The practical mechanics of bloodwork around peptide use: when to establish a baseline, how often to retest, the fasting and timing rules that make each marker readable, and the general routes people use to get tested.
13. Red flags: results that warrant stopping and seeing a clinician
The specific result patterns that the research and clinical communities most consistently treat as a signal to pause a compound and get professional evaluation — organized marker by marker, with the thresholds and the reasoning behind each.
14. Frequently asked questions
Straight answers to the questions researchers actually ask about peptides and bloodwork — from which single marker matters most to whether at-home kits are good enough and what to do when a peptide has no marker at all.

$39 covers this guide · $99 All-Access Lifetime includes this guide and every individual compound guide.

Get the Peptide Blood Marker Guide — $39 Browse individual guides

Guide FAQ

Quick answers about guide scope, access, and educational use context.

What blood tests should you get when taking peptides?

The commonly discussed baseline is a CBC, a comprehensive metabolic panel (liver and kidney markers), HbA1c with fasting glucose and insulin, a lipid panel, IGF-1, a hormonal and thyroid panel, and inflammatory markers (hs-CRP). Which of those matter most depends on the compound: IGF-1 for growth-hormone peptides, HbA1c and glucose for metabolic compounds, the sex-hormone panel for hormonal peptides. The safety markers — blood count, liver, kidney, thyroid — apply to almost everything. This is descriptive of what is monitored in research and community practice, not a personalized testing recommendation.

Do you need bloodwork to use peptides safely?

Most peptides sold for research use have little or no long-term human safety data, so there is no established monitoring standard. What can be said is that bloodwork is how the effect of a compound is objectively measured rather than guessed at — a baseline before starting, then periodic follow-ups compared against that baseline. Symptoms lag and are colored by expectation; a blood panel is an objective snapshot. Any actual testing and interpretation should be arranged with a qualified clinician and a licensed laboratory.

Which blood marker shows if a growth-hormone peptide is working?

IGF-1 is the master marker for the growth-hormone axis. GH itself is released in short pulses and a random draw tells you little, whereas IGF-1 reflects an integrated GH signal over roughly a day and is comparatively stable — which makes it the practical readout for whether a GHRH analog or secretagogue such as CJC-1295, ipamorelin, sermorelin or tesamorelin is raising GH output. It is read as a change from your own baseline, interpreted for your age and sex by a clinician.

How often should you test blood markers on peptides?

The pattern usually described is a baseline before starting, a follow-up some weeks into a compound once any effect would show, and periodic rechecks after that — with timing that matters for each marker (IGF-1 is stable; a random cortisol or prolactin is a single volatile moment). The guide's testing-logistics section lays out the cadence, fasting requirements, and how to get tested. Actual intervals are a clinical decision.

Why do two people reading the same blood result disagree about it?

Usually because of timing rather than the number. Several markers are only comparable to a result taken under the same conditions: fasting glucose, insulin and lipids depend on fasting state, prolactin and cortisol are time- and stress-dependent, hematocrit moves with hydration, and hs-CRP moves with any current infection. HbA1c reflects roughly the prior three months, so it cannot show a recent change at all. A result read without its conditions attached is not really a comparison — which is why an out-of-pattern single value is generally repeated before it is interpreted.

Can peptides affect your blood work?

Yes — that is the entire reason to monitor. Growth-hormone secretagogues can raise IGF-1 and nudge fasting glucose and hematocrit; GLP-1 compounds move glucose, insulin sensitivity and lipids; hormonal peptides can shift the sex-hormone panel; and several compounds can move liver, kidney or thyroid markers. Which markers move, and why that specific peptide moves them, is exactly what the per-peptide marker maps in the guide cover.

What is a baseline blood panel, and why does it matter more than the reference range?

A baseline is a full panel drawn before you start any compound. It matters more than the lab's population reference range because interpretation is almost always about the change from your own numbers, not about where you fall in a general population. A result inside the reference range can still be a meaningful move away from your baseline, and a result flagged high or low is an invitation to understand it — not, by itself, a verdict.

Does Medibact sell peptides?

No. Medibact supplies USP-grade bacteriostatic water for reconstitution, produced in an FDA-registered U.S. facility, and publishes educational research references — including a free guide for every compound in its library and this blood-marker guide. All content is research-use educational reference only: it describes what markers measure and how results are generally interpreted, and does not diagnose, treat, or provide medical or dosing advice.

Compliance and trust notes

Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.

Get Peptide Blood Marker Access View Full Library